Skip to main content

Advertisement

SpringerLink
Log in

Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Aims

The awareness of muscular adverse drug reactions (ADRs) increased since the withdrawal of cerivastatin, a HMG-CoA reductase inhibitor, from the market in August 2001. Our objectives were to assess the detection and incidence of muscular ADRs in a University Hospital using biochemical laboratory data and to evaluate the underreporting rate of drug-induced muscular disorders.

Methods

A prospective study was undertaken at Toulouse University Hospital, France, for 1 week per month from November 2001 to October 2002. Patients were selected by means of a computerized process using biochemical laboratory data based on serum creatine phosphokinase (CPK) values (over twofold normal). Medical records of all selected patients were then consulted.

Results

During the period of the study, 2017 CPK tests were performed, among which 171 values were over twofold normal corresponding to 129 patients. Because of lack of data, 26 patients were excluded. Among these patients (n=103), 28 cases of muscular ADRs were suspected, 22 of which were detected in outpatient departments. Four patients were totally asymptomatic and five had an increase of CPK over fivefold normal. Nine cases were classified as “serious”. Withdrawal of suspected drugs were done in 16 cases with regression of ADRs in 13 cases. According to hospitalization data, the incidence of muscular ADRs was estimated as 7.2 (2.6–15.7) per 10,000 inpatients and 9.3 (5.8–14.1) per 10,000 outpatients over 12 weeks. The involved drugs were mainly: statins (46.4%), fibrates (14.3%), antiretrovirals (14.3%), angiotensin-II receptor antagonists (10.7%), immunosuppressants (7.1%) or hydroxychloroquine (7.1). Only two cases, judged as “serious”, were spontaneously reported by physicians during the same period.

Conclusion

The results of this survey underline the importance to take into account drug hypothesis in muscular injuries diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Daniel P, Pratt O (1977) The metabolic homeostatic role of muscle and its function as a store of protein. Lancet 27:446–448

    Article  Google Scholar 

  2. Poels PJ, Gabreels FJ (1993) Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg 95:175–192

    CAS  PubMed  Google Scholar 

  3. Dayer-Berenson L (1994) Rhabdomyolysis: a comprehensive guide. ANNA J 21:15–18

    CAS  PubMed  Google Scholar 

  4. Charatan F (2001) Bayer decides to withdraw cholesterol-lowering drug. BMJ 323:359

    Article  Google Scholar 

  5. Begaud B (2000) Critères d’imputabilité des accidents d’origine médicamenteuse. Rev Prat 50:1803–1806

    CAS  PubMed  Google Scholar 

  6. Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1259

    CAS  PubMed  Google Scholar 

  7. Anonymous (2003) Dictionnaire VIDAL, 79th edn. O.V.P., Paris

  8. Tubert P, Bégaud B, Péré JEA (992) Power and weakness of spontaneous reporting: a probabilistic approach. J Clin Epidemiol 45:283–286

    Google Scholar 

  9. Haramburu F (1993) Estimation of under-reporting. Methodological approaches in pharmacoepidemiology: application to spontaneous reporting ARME-P. Elsevier Science Publishers, Amsterdam, pp 39–49

    Google Scholar 

  10. Thürmann P (2001) Methods and systems to detect adverse drug reactions in hospitals. Drug Saf 24: 961–968

    CAS  PubMed  Google Scholar 

  11. Azaz-Livshits T, Levy M (1998) Computerized surveillance of adverse drug reactions in hospital: a pilot study. Br J Clin Pharmacol 45:309–314

    Article  CAS  PubMed  Google Scholar 

  12. Tegeder I, Levy M, Muth-Selbach U (1999) Retrospective analysis of the frequency and recognition of adverse reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 47:557–564

    Article  CAS  PubMed  Google Scholar 

  13. Bagheri H, Michel F, Lapeyre-Mestre M et al (2000) Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol 50:479–484

    Article  CAS  PubMed  Google Scholar 

  14. Levy M, Azaz-Livshits T, Sadan B et al (1999) Computerized surveillance of adverse reactions in hospital: implementation. Eur J Clin Pharmacol 54:887–892

    Article  CAS  PubMed  Google Scholar 

  15. Salame G, Péré JC, Chaslerie A et al (1990) Liver injuries: a prospective study (abstract). J Clin Res Pharmacoepidemiol 4:133

    Google Scholar 

  16. Blanco JR, Zabalza M, Salcedo J et al (2002) Rhabdomyolysis of infectious and non-infectious causes. South Med J 95:542–544

    PubMed  Google Scholar 

  17. Gabow P, Kaehny W (1982) The spectrum of rhabdomyolysis. Medicine 61:141–152

    CAS  PubMed  Google Scholar 

  18. Phillips PS, Haas RH, Bannykh S et al (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581–585

    PubMed  Google Scholar 

  19. Wortmann RL (2002) Lipid-lowering agents and myopathy. Curr Opin Rheumatol 14:643–647

    Article  CAS  PubMed  Google Scholar 

  20. Thompson PD, Clarkson P, Richard H (2003) Statin-associated myopathy. JAMA 289:1681–1690

    Article  CAS  PubMed  Google Scholar 

  21. Evans M, Rees A (2002) Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 25:649–663

    CAS  PubMed  Google Scholar 

  22. Pasternak RC, Smith SC Jr, Bairey-Merz CN et al (2002) ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 106:1024–1028

    Article  PubMed  Google Scholar 

  23. Omar MA, Wilson JP, Cox TS (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35:1096–1107

    CAS  PubMed  Google Scholar 

  24. Ucar M, Mjorndal T, Dahlqvist R (2000) HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22:441–457

    CAS  PubMed  Google Scholar 

  25. Bannwarth B (2002) Drug-induced myopathies. Expert Opin Drug Saf 1:65–70

    CAS  PubMed  Google Scholar 

  26. http://www.agmed.sante.gouv.fr/htm/10/statine Muscular risk of statins. Cited June 4th, 2002

  27. Gaist D, Alberto Garcia Rodriguez L, Huerta C et al (2000) Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12:565–569

    Article  Google Scholar 

  28. Le Quintrec JS, Le Quintrec JL (1991) Drug-induced myopathies. Bailleres Clin Rheumatol 5:21–38

    Google Scholar 

  29. Serratrice G, Desnuelle C, Cros D (1984) Les atteintes musculaires d’origine médicamenteuse. Thérapie 39:677–687

    Google Scholar 

  30. Sieb JP, Gillessen T (2003) Iatrogenic and toxic myopathies. Muscle Nerve 27:142–156

    Article  PubMed  Google Scholar 

  31. Zuckner J (1990) Drug-induced myopathies. Semin Arthritis Rheum 19:259–268

    Article  CAS  PubMed  Google Scholar 

  32. Jeroen J, Toine CG (2002) Incidence and determinants of CK and liver function measurements in patients using statins. Pharmacoepidemiol Drug Saf 11:S75

    Article  Google Scholar 

  33. Paoletti R, Corsini A, Bellosta S (2002) Pharmacological interactions of statins. Atheroscler Suppl 3:35–40

    Article  CAS  PubMed  Google Scholar 

  34. Mora C, Rodriguez ML, Navarro JF (2001) Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin. Transplantation 72:551

    CAS  Google Scholar 

  35. Dalakas M, Illa I, Pezeshkpour G et al (1990) Mitochondrial myopathy caused by long term zidovudine therapy. N Engl J Med 322:1098–1105

    CAS  PubMed  Google Scholar 

  36. Lui W (1979) Phenothiazine-induced dystonia associated with an increase in serum creatine phosphokinase. Arch Dis Child 54:150–151

    CAS  PubMed  Google Scholar 

  37. Egan MF, Dargham AA, Kirch DG, Wyatt RJ (1993) Serum creatine phosphokinase elevations in patients with tardive dyskinesia. Br J Psychiatry 162:551–553

    CAS  PubMed  Google Scholar 

  38. Northoff G, Wenke J, Pflug B (1996) Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med 26:547–553

    CAS  PubMed  Google Scholar 

  39. Avina-Zubieta J, Johnson E, Suarez-Almazor M, Russel A (1995) Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. Br J Rheumatol 34:166–170

    CAS  PubMed  Google Scholar 

  40. Cacoub P, Sbai A, Azizi P et al (1999) Polymyositis induced by tiopronin. Presse Med 28:911–912

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d’informations sur le Médicament, Centre Hospitalier Universitaire, Faculté de Médecine, 37 allées Jules Guesde, BP 7202, 31073 , Toulouse Cedex 7, France

    A. Dugué, H. Bagheri, M. Lapeyre-Mestre, J. F. Tournamille & J. L. Montastruc

  2. Service de Médecine Interne, Centre Hospitalier Universitaire, Hôpital Purpan, Toulouse, France

    L. Sailler

  3. Laboratoire de Biochimie, Centre Hospitalier Universitaire, Hôpital Purpan, Toulouse, France

    G. Dedieu & J. P. Thouvenot

  4. Laboratoire de Biochimie, Centre Hospitalier Universitaire, Hôpital Rangueil, Toulouse, France

    R. Salvayre

  5. Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire, Toulouse, France

    P. Massip

Authors
  1. A. Dugué
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Bagheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Lapeyre-Mestre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. F. Tournamille
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Sailler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Dedieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Salvayre
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. P. Thouvenot
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Massip
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. L. Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Bagheri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dugué, A., Bagheri, H., Lapeyre-Mestre, M. et al. Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals. Eur J Clin Pharmacol 60, 285–292 (2004). https://doi.org/10.1007/s00228-004-0760-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0760-1

Keywords

Search

Navigation